Recorded Presentations from the NCCN 2025 Annual Congress: Hematologic Malignancies™

This congress focuses on updates to the NCCN Guidelines®, new and emerging therapeutic agents, and practical management strategies to ensure optimal patient outcomes.

Examining Health Policy, Payer, Provider, and Patient Perspectives in Indolent Non-Hodgkin’s Lymphoma

During this highly interactive session, panelists and experts representing policy makers, payers, providers, and patients will debate key challenges in iNHL management in light of recent health policy changes, new value-based models of care delivery, and unprecedented advances in targeted therapi

Recorded Presentation from Optimizing Patient Outcomes - The Changing Treatment Paradigm for Mantle Cell Lymphoma: Improving the Prognosis with Targeted Inhibitors and Evolving Immunotherapy Options
Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma with a variable course for which no standard treatment currently exists. This webinar can help you understand how to individualize and manage therapy for each patient.
NCCN Guidelines® Insights - B-Cell Lymphomas, Version 3.2025
These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.
Recorded Presentation from Optimizing Patient Outcomes - Transitioning CAR T-Cell and Bispecific Therapies to the Outpatient Setting
Treatment with CAR T-cell and bispecific therapies is a labor-intensive process and requires substantial interprofessional collaboration. Additional education and training of all involved clinical staff is essential to managing these patients as well as their subsequent toxicities.
Optimizing Patient Outcomes - The Changing Treatment Paradigm for Mantle Cell Lymphoma: Improving the Prognosis with Targeted Inhibitors and Evolving Immunotherapy Options
Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma with a variable course for which no standard treatment currently exists. This webinar can help you understand how to individualize and manage therapy for each patient.
Optimizing Patient Outcomes - Transitioning CAR T-Cell and Bispecific Therapies to the Outpatient Setting
Treatment with CAR T-cell and bispecific therapies is a labor-intensive process and requires substantial interprofessional collaboration. Additional education and training of all involved clinical staff is essential to managing these patients as well as their subsequent toxicities.
Archived NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease
T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.
Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease

The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphomas (DLBCL).

Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma?

Polatuzumab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) has emerged as a new first-line therapy option for patients with advanced stage diffuse large B-cell lymphomas (DLBCL).

Pages

Subscribe to RSS - Non-Hodgkin's Lymphoma